Insider Transactions in Q1 2026 at Monte Rosa Therapeutics, Inc. (GLUE)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
Markus Warmuth President & CEO |
SELL
Open market or private sale
|
Direct |
5,466
-0.29%
|
$125,718
$23.9 P/Share
|
|
Jan 05
2026
|
Edmund Dunn Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,039
-4.38%
|
$15,585
$15.17 P/Share
|
|
Jan 05
2026
|
Jennifer Champoux Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,629
-4.04%
|
$39,435
$15.17 P/Share
|
|
Jan 05
2026
|
Philip Nickson Chief Business & Legal Officer |
SELL
Open market or private sale
|
Direct |
3,155
-4.93%
|
$47,325
$15.17 P/Share
|
|
Jan 05
2026
|
Sharon Townson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,155
-4.44%
|
$47,325
$15.17 P/Share
|
|
Jan 05
2026
|
Filip Janku Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,155
-4.04%
|
$47,325
$15.17 P/Share
|
|
Jan 05
2026
|
Markus Warmuth President & CEO |
SELL
Open market or private sale
|
Direct |
10,135
-1.6%
|
$152,025
$15.17 P/Share
|
|
Jan 02
2026
|
Jennifer Champoux Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+35.0%
|
-
|
|
Jan 02
2026
|
Philip Nickson Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+30.43%
|
-
|
|
Jan 02
2026
|
Sharon Townson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+33.02%
|
-
|
|
Jan 02
2026
|
Filip Janku Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+28.39%
|
-
|
|
Jan 02
2026
|
Markus Warmuth President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+12.42%
|
-
|